These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1347 related articles for article (PubMed ID: 27277623)
1. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions. Neviere R; Yu Y; Wang L; Tessier F; Boulanger E Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623 [TBL] [Abstract][Full Text] [Related]
2. Aftermath of AGE-RAGE Cascade in the pathophysiology of cardiovascular ailments. Wasim R; Mahmood T; Siddiqui MH; Ahsan F; Shamim A; Singh A; Shariq M; Parveen S Life Sci; 2022 Oct; 307():120860. PubMed ID: 35940220 [TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs. Deluyker D; Evens L; Bito V Amino Acids; 2017 Sep; 49(9):1535-1541. PubMed ID: 28710551 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease. Prasad K; Tiwari S Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648 [TBL] [Abstract][Full Text] [Related]
5. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System. Yamagishi SI; Matsui T; Ishibashi Y; Isami F; Abe Y; Sakaguchi T; Higashimoto Y Curr Pharm Des; 2017; 23(8):1135-1141. PubMed ID: 27774900 [TBL] [Abstract][Full Text] [Related]
6. The dynamic roles of advanced glycation end products. Khalid M; Adem A Vitam Horm; 2024; 125():1-29. PubMed ID: 38997161 [TBL] [Abstract][Full Text] [Related]
7. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders. Yamagishi S; Taguchi K; Fukami K Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620 [TBL] [Abstract][Full Text] [Related]
8. Assay for advanced glycation end products generating intracellular oxidative stress through binding to its receptor. Kobori T; Ganesh D; Kumano-Kuramochi M; Torigoe K; Machida S Anal Biochem; 2020 Dec; 611():114018. PubMed ID: 33186591 [TBL] [Abstract][Full Text] [Related]
9. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646 [TBL] [Abstract][Full Text] [Related]
10. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680 [TBL] [Abstract][Full Text] [Related]
11. Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression. Muthyalaiah YS; Jonnalagadda B; John CM; Arockiasamy S Glycoconj J; 2021 Dec; 38(6):717-734. PubMed ID: 35064413 [TBL] [Abstract][Full Text] [Related]
12. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Khalid M; Petroianu G; Adem A Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131 [TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products (AGEs) and their involvement in liver disease. Hyogo H; Yamagishi S Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847 [TBL] [Abstract][Full Text] [Related]
14. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation. Yamagishi SI; Sotokawauchi A; Matsui T Mini Rev Med Chem; 2019; 19(13):1040-1048. PubMed ID: 30854960 [TBL] [Abstract][Full Text] [Related]
15. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women. Pertynska-Marczewska M; Merhi Z Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634 [TBL] [Abstract][Full Text] [Related]
16. Activation of the receptor for advanced glycation end products and consequences on health. Wautier MP; Guillausseau PJ; Wautier JL Diabetes Metab Syndr; 2017; 11(4):305-309. PubMed ID: 27612394 [TBL] [Abstract][Full Text] [Related]
17. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions. Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668 [TBL] [Abstract][Full Text] [Related]
18. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure. Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033 [TBL] [Abstract][Full Text] [Related]
19. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Yamagishi S; Fukami K; Matsui T Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643 [TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products receptor RAGE controls myocardial dysfunction and oxidative stress in high-fat fed mice by sustaining mitochondrial dynamics and autophagy-lysosome pathway. Yu Y; Wang L; Delguste F; Durand A; Guilbaud A; Rousselin C; Schmidt AM; Tessier F; Boulanger E; Neviere R Free Radic Biol Med; 2017 Nov; 112():397-410. PubMed ID: 28826719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]